Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial combines four drugs — blinatumomab, methotrexate, cytarabine, and ponatinib — which is a pretty intensive regimen; can you walk me through what side effects I should realistically expect from this combination, and are there any that are specific to ponatinib, like heart or blood vessel problems, that I should be aware of?
2. 2Since this is a Phase 2 trial, researchers are still building evidence on how well this treatment works and how safe it is — given that, how does the risk-benefit picture here compare to what's currently considered standard of care for my specific situation, whether that's newly diagnosed Ph-positive ALL or relapsed disease?
3. 3The trial is measuring whether patients achieve a 'complete molecular response,' meaning no detectable BCR-ABL — how likely is it that I might reach that goal, and what happens in this trial if I don't respond or if my disease comes back?
4. 4This study includes both newly diagnosed patients and people with relapsed or refractory ALL, which are very different situations — does my doctor think my specific disease history and BCR-ABL status make me a good candidate to even discuss with the trial team, or would a different approach make more sense first?
5. 5If I were to discuss enrolling in this trial, what would the treatment schedule actually look like day-to-day — how often would I need to come in, are there parts of this regimen that require hospitalization, and how might that affect my ability to work or care for my family?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.